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Abstract
Background: Joint impact injuries initiate a progressive articular damage finally leading to post-traumatic
osteoarthritis (PTOA). Racehorses represent an ideal, naturally available, animal model of the disease. Standardbred
racehorses developing traumatic osteoarthritis of the fetlock joint during the first year of their career were enrolled
in our study. Age-matched controls were contemporarily included. Biomarker levels of equine osteoarthritis were
measured in serum and synovial fluid (SF) at baseline, and repeated yearly over the next 4 years of training (from
T1 to T4). The effect of time and disease on the biomarker concentrations were analysed, and their relationship
with clinical and radiographic parameters were assessed. We hypothesized that the kinetics of pro-inflammatory
cytokines and structural biomarkers of joint disease would demonstrate progression of degenerative joint status
during post-traumatic osteoarthritis and clarify the effect of early joint trauma.
Results: The concentrations of IL1-ß, IL-6, TNF-α in the SF of PTOA group peaked at T0, decreased at T1, and
then progressively increased with time, reaching levels higher than those observed at baseline starting from T3.
CTXII and COMP levels were similar in PTOA and control horses at baseline, and increased in serum and synovial
fluid of PTOA horses starting from T2 (serum and synovial CTXII, and serum COMP) or T3 (synovial COMP). The
percentual change of TNF-α in the SF of the affected joints independently contributed to explaining the
radiological changes at T3 vs T2 and T4 vs T3.
Conclusions: Temporal changes of selected biomarkers in STBRs with an acute episode of traumatic fetlock OA
demonstrated that long-term increased concentrations of inflammatory cytokines, type II collagen fragments and
COMP, in the SF and serum, are related to PTOA. Based on the observed decrease in inflammatory merkers at T1, we
hypothesize that the progression of PTOA could be effectively modulated by proper treatment strategies. Annual
variations of synovial concentration of TNF-α can reliably predict radiographic progression of PTOA.
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Background
Osteoarthritis (OA) is a chronic and progressive disease
that begins many years before structural changes in the
whole joint are detectable. Animal models, in which
hyaline articular cartilage (HAC) was experimentally im-
pacted [1–4] or joint instability was experimentally in-
duced [5], showed rapid progression of joint damage, at
the level of the cartilage and subchondral bone [2, 6–8].
Surgical management to achieve stabilization of the knee
failed to abrogate the development of post-traumatic
osteoarthritis (PTOA) [9, 10], indicating that a biochem-
ical disturbance in the HAC of the affected joint is impli-
cated in the accelerated rate of joint degeneration.
Longitudinal studies in human medicine have shown that
the initial cartilage damage progresses to an established
degenerative joint disease (DJD) in the hip [11] and knee
joints [11, 12]. These themes of research are central to
understand the optimal strategy for preventing joint de-
generation [13], since both the molecular basis and the
time frame of this progression are still not well-defined.
A single articular cartilage impaction produces imme-
diate matrix disruption resulting in cell death at the
impaction site and further radial progression of cell
apoptosis to non-impacted area of the HAC [1, 13]. This
is demonstrated also in the spontaneous OA of the knee,
at the specific sites of cartilage damage [14]. Cell death
results in activation of caspase [15], depleting the cartilage
of the cells that are able to repair the matrix. Resident
chondrocytes are activated to produce inflammatory cyto-
kines, such as IL-1ß, IL-6, TNF-α [16]. These cytokines
participate to recruitment of inflammatory cells, and
activation of intracellular pathways promoting the expres-
sion of metalloproteinases [MMPs −1, −3, −9, −10, −13
and aggrecanases (ADAMTs)] activating procollagenase
[10, 17] and cathepsin K [18], lastly degrading proteogly-
cans (PGs) and type II collagen, in the cartilage matrix.
Further mechanical stress on the weakened cartilage
matrix produces progressive loss of the HAC [13, 19],
and the release of extracellular matrix molecules in the
synovial fluid (SF). In PTOA these molecules included
type II collagen fragments, fibronectin, fibromodulin,
hyaluronan and lubricin. As fibronectin activates the
complement cascade, collagen fragments up-regulated
MMPs in chondrocytes via MAPK38 and Nf-kB signal-
ling [20, 21], further switching the cartilage from the
anabolic to the catabolic state.
Considering animal models of PTOA, racehorses sus-
taining repetitive impact joint injuries, during their ath-
letic career, are likely to develop DJD shortly after the
initial inflammatory event affecting the joints [2, 4, 6, 7].
This progression was bound to occur at a much faster
rate than in humans [22, 23], although there are cur-
rently not enough investigations and consensus about
this statement.
Assaying blood, urine or SF biochemical markers
could reflect qualitative and/or quantitative changes
within the joint [22, 23], providing information on
disease activity in the joint compartment. Biomarkers
reflecting type II collagen degradation (i.e. CTXII) are
currently considered the most promising index of MMPs
activity, both in human and animal models of OA [24, 25].
Non-collagenous proteins like complex oligomeric matrix
protein (COMP), released into the SF during HAC deg-
radation [26], may also indicate an increase matrix turn-
over in the HAC in response to exercise [27, 28], making
difficult to discriminate between normal and OA-affected
patients. In most cases a substantial overlap with controls
indicates that a single biomarker alone may have limited
diagnostic potential [29], preferring the combination of
different biomarkers for assessing disease activity on the
individual level [30, 31]. Practical application of bio-
markers assessment was found very promising in race-
horses, where they could indicate the pattern of disease
activity (inflammatory versus degradative status of the
joint) during PTOA and verifying treatments efficacy like
in other animal models [32], but they continue to be of
limited use due to the insufficiency of longitudinal studies.
Objective of the study
As a primary objective, this study will compare kinetics
of structural biomarkers and pro-inflammatory cytokines
in the SF and bloodstream of a group of racehorses with
fetlock joint injury versus a group of controls, monitored
during 5 years of racing career from the early stages of
disease onset. Considering only the PTOA group, this
study will:
1) Evaluate the reliability of a combination of
pro-inflammatory cytokines (IL-1ß, IL-6, and
TNF-α) and cartilage degeneration biomarkers
(COMP and CTXII) to define disease activity and
predict PTOA progression in comparison to
radiographic assessment of the joints;
2) Assess the relationship between serum and SF
biomarkers at the same time-point;
3) Investigate the relationship between the
inflammatory status and the HAC degradation in
the fetlock joints affected by PTOA, during active
training, in order to modulate joint therapy.
Hypothesis of the study
We hypothesised that repetitive biomarker immunoassays,
during active training, could confirm progressive degener-
ation in PTOA-affected joints following a spontaneous
joint injury, in comparison to healthy controls. Further-
more, in evaluating the inflammatory and/or degradative
status of the HAC we would be able to characterize dis-
ease activity, and define the phenotype of PTOA during
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disease progression. Lastly, our hypothesis was that target-
ing pro-inflammatory cytokines, in combination to train-
ing suspension, would be effective in PTOA prevention.
Methods
Animals and experimental design
This is a longitudinal and cross-sectional cohort study.
Horses enrolled in this study were part of a larger cohort
of animals monitored from September 2008 to August
2013 and previously described [33]. Racehorses younger
than 3-years old experiencing a spontaneous traumatic
fetlock OA were assigned to the PTOA group at the mo-
ment of the lesion (T0). The diagnostic criteria for diag-
nosing traumatic fetlock OA were a significant clinical
improvement of the lameness score after intra-articular
(IA) diagnostic analgesia or low meta-carpal/tarsal nerve
block, and the presence of one of the following findings:
osteochondral fragmentation at the proximal and dorsal
border of the proximal phalanx, detection of osteophytes
and/or entesiophytes at the articular margins at the level
of the capsular insertions, ultrasonographic signs of
chronic synovitis, and signs of subchondral bone trauma
at the magnetic resonance imaging. Animals with devel-
opmental osteochondral pathologies and/or major frac-
tures affecting the target joints were excluded from the
study. For each PTOA horse included in the study, a
control subject from the same training centre was en-
rolled concomitantly. Control horses (C group) were
randomly selected amongst age-matched STBRs, which
were sound at the time of their physical examinations
and radiographically normal. In each control it was se-
lected a fetlock joint with the criterion of respecting the
distribution between front- and hindlimbs observed in
the studied horses. Animals in both groups, which sus-
tained major musculoskeletal injuries and were retired
before the completion of the study were excluded from
the cohort. Likewise, animals that received IA corticoste-
roids in the targeted joints and animals tested positive
for doping were ruled out. All joint medications admin-
istered to racehorses included in the PTOA-group dur-
ing the study period complied with the local anti-doping
agency guidelines1. Racehorses in the PTOA-group re-
ceived a personalized joint treatment immediately after
the acute trauma with a simple training suspension, and
IA joint medication alone, or a combination of arthro-
scopic surgery and joint medications associated to train-
ing suspension during the period of joint rehabilitation.
Since their enrolment in the study, the animals were
strictly monitored to assess the progression of degenera-
tive changes in the target joints. Specifically, they under-
went yearly clinical and radiographic examination, as well
as blood and synovial fluid sampling for five consecutive
years (Fig. 1). All the enrolled racehorses underwent regu-
lar training during throughout the study period.
Clinical and radiographic assessment of the joint
Horses were observed trotting on a straight line (hard
surface) to assess lameness severity, before and immedi-
ately after distal limb flexion tests. Video-recordings
were taken of each clinical examination and blindly ana-
lysed by one operator, unaware of the horse ID, at the
end of the study. Lameness was marked with 0 to 5
points as advised by the American Association Equine
Practitioner [34] (Table 1). The response to the flexion
tests was marked 0 to 3 in relation to the increase in
lameness score of the animal (where 0 = negative response
and 3 =markedly positive response).
A semi-quantitative radiographic score ranging from 0
to 33 points (Table 2), modified from the one previously
adopted by Cleary [27], was used to assess radiographic
severity of OA. The radiograms were anonymous with
regard to the patients’ data and chronology, and were
evaluated blindly. Two experienced clinicians defined
the radiographic scores by consensus.
Biological sample processing
Blood and SFs were collected during the first lameness
investigation (T0) in the PTOA group and were then re-
peated during four consecutive years (T1 to T4). In the
C group, SFs were collected at T0 randomly from one of
the fetlock joints, and later assessments were repeated in
the same joint. Synovial fluid was taken aseptically from
the proximal palmar/plantar pouch of the fetlock joints
with the joint slightly flexed, collected in EDTA-
containing tubes and placed on ice. Blood was obtained
from jugular venepuncture using EDTA-tubes and
placed on ice. Before each sampling, the horses were
housed in a stall for 2 consecutive days and they were
not exercised. Within 1 h from collection, the blood was
centrifuged at 3500 g x for 12 min at 4 °C. Serum ali-
quots (5x1 ml) were collected in plain tubes and were
stored at −80 °C. Synovial samples were centrifuged at
3200 g x for 10 min at 4 °C to remove cells and debris
and were mixed with 1 mM phenylmethylsulphonyl-
fluoride (PMSF, an inhibitor of serine proteases), and
5×1-ml aliquots were stored at −80 °C. Before the ELISA
tests, the SF was treated with hyaluronidase (Hyaluroni-
dase from bovine testes, Sigma H3884, Sigma-Aldrich,
Saint Louis, Missouri, USA) at a concentration of 20 UI/
ml for 30 min at 37 °C to reduce their viscosity and were
diluted 1:2 with HPE-0.1375 % Tween buffer solution
(Sanquin Reagents, Amsterdam, Netherlands).
ELISA tests
Interleukin-1ß concentrations in the collected samples
were determined using a commercial direct ELISA kit
(ABIN572441, antibodies-online Inc., Atlanta, Georgia,
USA) with a rabbit polyclonal antibody raised against
equine IL-1ß. Interleukin-6 concentrations were measured
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with a commercially available sandwich ELISA kit using a
mouse monoclonal antibody raised against equine IL-6
(SEA079Eq, USCN Life Science Inc., Wuhan, China).
Tumour necrosis factor-α concentrations were measured
with a direct ELISA kit (bs-2081R, Bioss Inc., Woburn,
Massachusetts, USA) using a rabbit anti TNF-α polyclonal
antibody. Cartilage oligomeric matrix protein concentra-
tions were determined with a commercially available
Table 1 Lameness score adopted in our study (AAEP score)
Score 0 = sound in all circumstances (walk, trot and fast work at
the racetrack)
Score 1 = lameness difficult to detect and not consistently obvious,
regardless of circumstancesa
Score 2 = lameness undetectable at walk and difficult to detect at
trot in straight line, but consistently apparent under certain
circumstances of fast worka
Score 3 = lameness consistently detectable at trot in straight line and
under all circumstances
Score 4 = obvious lameness at walk
Score 5 = minimal weight bearing
aall racehorses with low-grade lameness scores were observed during fast
work at the racetrack for proper assessment of 1/5 and 2/5 lameness scores
Table 2 Radiographic score adopted to assess fetlock joint OA
in horses based on standard x-ray examinations
Radiographic parametersa Score
Joint space narrowing 0 to 3
Osteophytes number 0 to 3
Osteophytes size 0 to 3
Enthesiophytes number 0 to 3
Enthesiophytes size 0 to 3
Subchondral bone changes at the palmar/plantar aspect of the
metacarpal/metatarsal condyles
0 to 3
Osteochondral fragmentations number 0 to 3
Osteochondral fragmentations size 0 to 3
Soft tissues swelling 0 to 3
Supracondylar bone resorption 0 to 3
Proximal sagittal crest osteolysis 0 to 3
aall parameters were scored 0 (normal) to 3 (pathologic) and summed
up together
Fig. 1 Schematic design of the study
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sandwich ELISA kit (MBS006795, MyBioSource Inc., San
Diego, California, USA) using a monoclonal antibody
against the equine COMP. Cross-linked C-telopeptide
fragments of type II collagen concentrations were assessed
with a sandwich ELISA kit (code AC-08 F1, Serum Pre-
Clinical Cartilaps, IDS, Boldon, UK) using a monoclonal
antibody raised against CTXII fragments (6 amino acids
of the sequence EKGPDP) as described previously. All of
these assays had been previously validated for use with
equine serum and SF [27, 35–37]. Absorbance was mea-
sured at 450 nm with a microplate reader. Each sample
was analysed in duplicate. Positive, negative and blank
controls were included on each plate in duplicate. The
intra- and inter-assay coefficients of variability (%CV)
were calculated for each series of assays.
Statistical analysis
Values are expressed as median and 95 % C.I. Continu-
ous variables were tested for normality with the Shapiro-
Wilk normality test. Abnormally distributed variables
underwent Log10 transformation. Effect of time and
group on biomarker levels were studied with two-
way ANOVA and Bonferroni post-tests for multiple
comparisons.
Considering only the PTOA group, a mixed regression
model was employed to analyse how biomarkers,
radiographic score and clinical scores were associated
during the time of the study, with time and subjects as
fixed effects. A general linear model was used to inves-
tigate how each biomarker independently contributed
to explain radiological progression in the same group
of animals.
Correlations between SF and the serum concentrations
of each biomarker, at different time points, were eval-
uated using Pearson correlation tests in the PTOA
group. Correlations between different biomarkers at
each time point were calculated using Spearman cor-
relation tests to investigate the associations between
pro-inflammatory cytokines and structural biomarkers
of HAC degradation. P-values <0.05 were considered
statistically significant.
Results
Thirty-seven animals fulfilled the inclusion criteria for
the PTOA group during the study period. However, 9
racehorses sustained orthopaedic injuries preventing fur-
ther training and were retired, and 3 animals received
corticosteroids IA, causing their exclusion from the
study. Finally, only 25 racehorses were included in the
PTOA group. Among the control horses, of the 37 en-
rolled initially, only 30 fulfilled the inclusion criteria, but
only 16 animals completed the 5-years period of training
studied. In the PTOA group only 21 % of the horses
received an arthroscopic surgery to remove an osteo-
chondral fragmentation associated to the acute joint
trauma, as 78 % of the horses received multiple joint
medications, using autologous Interleukin-1 Receptor
Antagonist Protein (IL-1Ra) or hyaluronic acid. IL-1Ra
treatments were prepared according to the instructions
of the manufacturer (Orthokine Vet IRAP 60, DE). All
horses that had a joint injury were initially managed with
a reduced exercise regimen in addition to IA medication
or surgery (arthroscopy) and a variable period of box-
rest and rehabilitation (i.e. walking, swimming, or water-
treadmill from 6 to 12 weeks after surgery and from 1 to
3 weeks after joint medication) before to gain progres-
sive training. All the animals were sound when they were
back in training. Clinical details of the horses studied are
summarized in Table 3.
Clinical evaluation of lameness in the PTOA vs. C groups
In the C group, all of the horses were clinically sound
and did not respond to flexion tests during the whole
study period. In the PTOA group, the lameness score
was highest initially, returned to baseline value at T1–
T3, but increased again at T4. Lameness scores at T4
were significantly higher than at T1, T2, and T3
(Table 4). The flexion test responses at T0 were greater
than at T1, T2, and T3. Also, the flexion test response
was greater at T3 than at T2, and at T4 than at T1, T2,
and T3 (Table 5).
Radiographic evaluation in the PTOA vs. C groups
In the C group, the radiographic scores remained stable
throughout the study period. In the PTOA group, the
radiographic scores were lower at T0 compared to T2,
T3, and T4 (Fig. 2).
Synovial fluid and serum biomarker concentrations in the
PTOA vs. C groups
Biomarkers concentrations were always within the min-
imal detection values of the immunoassays. An intra-
assay %CV < 10 % and an inter-assay %CV < 15 % were
considered acceptable. A significant effect of both group
(PTOA vs. C) and time was identified for the synovial
concentrations of IL-1β (p < 0.0001), IL-6 (p < 0.0001),
TNF-α (p = 0.0025 and p < 0.0001), COMP (p = 0.001
and p = 0.0001), and CTXII (p < 0.0001) (Fig. 3). The
concentrations of IL-1β, TNF-α, COMP, and CTXII in
SF did not vary with time in the C group, demonstrating
that age and exercise per se do not affect the SF concen-
trations of these biomarkers in healthy horses. Only IL-6
concentrations significantly increased with time in the
SF of the C group, with the values detected at T3 and T4
significantly higher than those detected at T0 (p < 0.05
and p < 0.001, respectively).
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In the PTOA group the effect of acute joint injury in-
duced a significantly increase in SF levels of IL-1β and
IL-6 at T0, which persisted at T1, only for IL-6. Levels
of IL-1β in PTOA-affected joint returned to pre-injury
levels 1 year after the acute joint trauma. At T2, levels of
IL-6 and CTXII in SF were significantly elevated in the
PTOA-affected joints compared to exercise-alone joints
of the C group. At T3, concentration of IL-1β, IL-6,
TNF-α, COMP and CTXII in SF were all significantly
elevated in the PTOA-affected joints compared to C
group and these difference persisted also in the last
measurement.
Table 3 Baseline clinical characteristics of racehorses at the time of inclusion and during the study period
PTOA-group
(n = 37)
Healthy subjects
(n = 37)
Standardbred racehorses with at least 6 months of training at the time of inclusion, no. (%) 35 (94 %) 37 (100 %)
Gender, no. (%) male/no. (%) female/no. (%) gelding/no. (%) 16 (43 %)/12 (32 %)/
9 (24 %)
11 (29 %)/16 (43 %)/
10 (27 %)
Age at the moment of the enrolment (months) 32 (27–35) 34 (29–35)
Disease duration, referring to the lameness identification (days) 5 (2–19) –
Administration of anti-inflammatory therapy before diagnosis, no. (%) 5 (14 %) –
Lameness score at clinical examination (0–5 scale) 2 (2–3) 0
Flexion test response in the affected leg at clinical examination (0–3 scale) 2 (1–3) 0
Horses sound after intra-articular analgesia with mepivacaine, no. (%) 22 (61 %) –
Horses sound after low 4-points-metacarpal (6-points-metatarsal) nerve block, no. (%) 15 (39 %) –
Radiographic score of the affected fetlock joint at T0 (0–33 scale) 5 (2–11) 0
Osteochondral fragmentation at the dorsal border of the proximal phalanx, no. (%) 9 (24 %) –
MRI findings of subchondral bone trauma in the metacarpal/metatarsal epiphysis or subchondral
bone of the proximal phalanx, no. (%)
3 (8 %) –
Horses with haemarthrosis in the synovial fluid at clinical presentation, no. (%) 4 (11 %) –
US findings of fetlock joint synovitis (thickening of the dorsal plica, increased synovial fluid) 29 (76 %) –
Arthroscopic surgery to remove osteochondral fragmentation, no. (%) 8 (21 %) –
Animals treated intra-articularlya, no. (%) 28 (76 %) –
Animal treated intravenously or intramuscularlyb, no. (%) 8 (21 %) –
Days of box-rest after traumatic fetlock OA, before to gain training 42 (28–198)
Animals retired because additional muscoloskeletal injuries or other medical problems during
the study period, no. (%)
9 (24 %) 17 (46 %)
Animals exluded because they were positive at doping controls/received corticosteroids
intra-articularly, no. (%)
3 (8 %) 4 (11 %)
Animals that completed the time-course of the study, no. (%) 25 (68 %) 16 (43 %)
Abbreviations: MRI magnetic resonace imaging, US ultrasound
aDrugs administered intra-articularly were: Interleukin-1-Receptor-Antagonist-Protein (IL-1Ra), hyaluronate, polysulfated glycosaminoglycan
bDrugs administered intramuscularly or intravenously were: Tiludronate (IV or IM) and polysulfated glycosaminoglycan (IV)
Except where indicated otherwise, values are the median (range or percentage in brackets) in all the patients
Table 4 Average Lameness score over 5 years of the study, in
the Control and PTOA groups
PTOA group (n = 25) Control group (n = 16)
T0 2.0 (2.0–3.0)a 0.0 (0.0–0.0)b
T1 0.0 (0.0–0.0)b 0.0 (0.0–0.0)b
T2 0.0 (0.0–0.0)b 0.0 (0.0–1.0)b
T3 0.0 (0.0–1.0)b 0.0 (0.0–0.0)b
T4 1.0 (1.0–2.0)a 0.0 (0.0–1.0)b
Values are reported as median with the corresponding 25 % and 75 %
percentile (parenthesis). Comparison intra- and inter-groups are shown. Super-
script letters that are different show a significant difference (p-value <0.05) be-
tween groups for this outcome variable
Table 5 Average Flexion tests response over 5 years of the
study, in the Control and PTOA groups
PTOA group (n = 25) Control group (n = 16)
T0 2.0 (1.0–3.0)a 0.0 (0.0–0.0)b
T1 0.0 (0.0–1.0)b 0.0 (0.0–1.0)b
T2 0.0 (0.0–1.0)b 0.0 (0.0–0.0)b
T3 1.0 (1.0–1.0)c 0.0 (0.0–1.0)b
T4 2.0 (1.0–2.0)a 0.0 (0.0–0.0)b
Values are reported as median with the corresponding 25 % and 75 %
percentile (parenthesis). Comparison intra- and inter-groups are shown. Super-
script letters that are different show a significant difference (p-value <0.05) be-
tween groups for this outcome variable
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As for serum samples, a significant effect of both group
(PTOA vs. C) and time was noticed on the concentrations
of IL-1β (p < 0.0001), IL-6 (p = 0.04 and p = 0.03), TNF-α
(p = 0.0002 and p < 0.0001), COMP (p = 0.0002 and p <
0.0001), and CTXII (p = 0.0025 and p < 0.0001) (Fig. 3). The
serum concentrations of IL-1β, IL-6, TNF-α, COMP, and
CTXII did not vary over time in the C group, proving that
age and exercise per se do not affect the concentrations of
these biomarkers in healthy horses. There was no increase
in pro-inflammatory cytokines in serum of PTOA-affected
horses compared to exercise alone horses at T0, T1 and T2.
Only at T4, levels of IL-1β in serum were elevated in
PTOA-affected animal compared to C horses. There were
no significant increases in serum levels of IL-6 in horses
with PTOA, during all the study. TNF-α level in serum
started to rise significantly in PTOA-affected animals at T3
and differences persisted at T4, similarly to the values of
CTXII. In PTOA group the effect of disease induced a
significantly rise in serum levels of COMP at T2, which
persisted throughout the duration of the study.
Correlation between synovial fluid and serum biomarkers
There were significant correlations between SF and the
serum levels of IL-1β in horses with PTOA, only at T4.
The mean level of IL-1β in the SF of PTOA affected joints
compared to serum, for the same horses, was 2.5-fold
higher. As for IL-6, its serum concentration reflected SF
levels at T0 and T4 only in the PTOA group, and the
mean level of IL-6 were 2.8-fold and 2.6-fold higher in the
SF compared to the serum, respectively. CTXII levels in
serum reflected SF levels in PTOA-affected joint at T3
and T4, and the mean levels of CTXII were 5.8-fold and
5.6-fold higher in the SF compared to serum, respectively.
An exhaustive summary of the results of correlation tests
between serum and SF biomarkers at different time-points
is provided in Table 6.
Temporal changes in pro-inflammatory cytokines and
structural biomarkers during training and correlations
with radiographic and clinical scores
All data from T0 to T4 in PTOA group were trans-
formed and expressed as percentage change compared
to the value of the same variable at the previous time-
point (Fig. 4). In the early stage of PTOA, SF level of
pro-inflammatory cytokines decreased in the first year
of training, following joint medications or arthroscopic
surgery (IL-1β and IL-6 at T1 were significantly lower
than each baseline level). As expected, indices of OA
disease activity increased following the acute joint in-
jury and became significantly elevated at T2 (CTXII)
and at T3 (COMP), gradually increasing until the end
of the study. Interestingly, levels of pro-inflammatory
cytokines increased significantly starting from T2 (IL-
1β) to T3 (IL-6, TNF-a) and demonstrated a quite
similar pattern that CTXII and radiological score,
meaning that structural joint damage, particular in
term of cartilage destruction is associated with the
degree of joint inflammation, during the progression of
PTOA. Of note, the lameness score increased only
after the structural damage and the joint inflammation
progressed for many years, at the end-point of the
study. The pattern of the pro-inflammatory cytokines
and the structural biomarkers in serum appeared to
synchronize to SF changes, starting from T2. Only
level of COMP in serum remained unchanged during
5 years.
Correlations between the variation of a single bio-
marker between 2 years (i.e. T0-T1, expressed as ΔT0-T1)
Fig. 2 Total radiographic score of the fetlock joints over 5 years of the study in the Control and PTOA groups. Data are presented as mean, and
95 % confidence interval. P-values were determined by comparisons of the groups at any time point and in the groups, against the value at T0,
with two-way ANOVA. Stars (*) represent significant differences between the 2 groups at the same time point (*:p < 0.05; **:p < 0.01; ***:p < 0.001).
Symbols (§) represent significant differences with T0 in the same group (§:p < 0.05; §§:p < 0.01; §§§:p < 0.001)
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Fig. 3 (See legend on next page.)
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and the variation of radiographic scores between the
subsequent 2 years (i.e. T1-T2) are shown in Table 7.
In the SF, the percentage increase of TNF-α level at
T3 vs. T2 was significantly correlated with the per-
centage increase of the radiographic score at T4 vs.
T3. Moreover, a trend to significance was identified
between the percentual variation of synovial TNF-α at
T2 vs. T1 and the percentual variation of radiographic
score at T3 vs. T2. In serum, the percentage variation
of IL-6 at T3 vs. T2 was significantly correlated with
the percentage change of the radiographic score at T4
vs. T3. No others significant correlations were noted
between the percentage variation of biomarkers levels
in SF and serum and the percentage changes of the
clinical scores in the PTOA group.
Association between pro-inflammatory cytokines and
structural biomarkers in the serum and synovial fluid
of the PTOA group
Significant correlations were observed among various
biomarker in the serum and SF at different time-points
(Table 8). Specifically, significant correlations between
pro-inflammatory cytokines were detected: IL-1β to IL-6
at T0, both in serum and SF, IL-1β to TNF-α at T3 and
T4, only in the SF, and IL-6 to TNF-α at T3, only in
serum. Interestingly, correlations between structural
biomarkers and pro-inflammatory cytokines were ob-
served. Strong significant correlations were noted
between CTXII and TNF-α in the SF, both at T3 and at
T4, and a moderate correlation at T0. Moderate signifi-
cant correlations were observed for the IL-1β and
COMP in the SF, at T0, T1, T3 and T4. Similarly, sig-
nificant correlations were observed between IL-6 and
CTXII in the SF, only at T2 and between IL-6 and
COMP, at T0, both in serum and SF, and at T2 and T4,
only in serum. No significant correlations were ob-
served between structural biomarkers.
Discussion
This study demonstrates that an acute episode of trau-
matic OA, in the first year of training, is able to induce
an accelerated progression of PTOA in the affected fet-
lock joints, from a normal state to an end-stage disease,
within 4 years. This is the first study in which the long-
term consequences of an impact joint injury have been
evaluated in STBRs with spontaneous PTOA, regularly
trained after a rehabilitation period, and using biomarkers
to assess disease activity. Previous studies focused on OA
biomarkers in experimental horse models spread their
observations to a limited number of weeks following
the acute joint injury [2, 7, 27, 38–40].
Osteoarthritis progression was not characterized by
linearity, demonstrating that early inflammation and
structural changes in the HAC are not ever associated,
and they could be effectively modulated by the intensity
of training and therapeutic management. Traumatic OA
is characterized by a peak of pro-inflammatory cytokines
in the SF, as previously reported [16, 41]. Despite this
finding, 1 year after the impact-injury, there were no
radiographic and biochemical signs of joint disease in
the fetlock joints that sustained traumatic injuries, and
signs of lameness subsided. At this stage, PTOA-affected
animals were all undergoing new bouts of repetitive
exercise. Our features confirmed that joint injury at a
young age decreases the tolerance of the cartilage matrix
to the increased magnitude of mechanical stress, as new
bouts of workloads are associated with structural dam-
age of the HAC. Structural changes in the HAC of the
PTOA-affected joints, based on CTXII level in the SF,
started rise 2 years after the acute joint trauma. This
corresponds to the age of 4 years old, when those race-
horses joined the higher speed at races. Previous studies
(See figure on previous page.)
Fig. 3 Values of inflammatory cytokines and structural biomarkers in synovial fluid and serum. Healthy controls (C group; n = 16) and racehorses
with traumatic osteoarthritis at the fetlock joint (PTOA group; n = 25) are reported during the timeframes of the study (T0 to T4). Values in
synovial fluid are shown in panels a, c, e, g, and i. Values in serum are shown in panels b, d, f, h, and l. Data are presented as median, and
25th to 75th percentiles (whiskers). P-values were determined by comparisons of the groups at any time point and in the groups at different
time points with two-way ANOVA. Stars (*) represent significant differences between the 2 groups at the same time point (*:p < 0.05; **:p < 0.01;
***:p < 0.001). Symbols (§) represent significant differences with T0 in the same group (§:p < 0.05; §§:p < 0.01; §§§:p < 0.001)
Table 6 Synovial Fluid and Serum correlations at different
time-points
Synovial fluid/Serum
concentration
T0 T1 T2 T3 T4
PTOA group IL-1b – – – – r = 0.43*
IL-6 r = 0.43* – – – r = 0.51**
TNF-a – – – r = 0.53** –
COMP – – – – –
CTXII – – – r = 0.57** r = 0.63***
C group IL-1b – – – – –
IL-6 – – r = −0.85* – –
TNF-a – – – r = 0.87* –
COMP – – – – –
CTXII – – – – –
Correlations of pro-inflammatory cytokines and structuralbiomarkers values, in
the synovial fluid and serum, at different time-points, in both the PTOA and C
groups, over the 5 years of the study. P-values and coefficient of regression (r)
are shown. Significant correlations are represented as bolded R-values with
the superscript star. Key: *:p < 0.05;**:p < 0.01;***:p < 0.001
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in animal models provided evidence that damage to the
collagen network of the HAC is an early event occurring
concurrently to the acute joint injury [22]. Also, an ex-
perimental model of OA in Thoroughbred racehorses
showed an increase in aggrecan (CS846-epitope), COMP,
and collagen type II fragments (C1, 2C), both in serum
and SF, which were able to discriminate horses with OA
vs. exercise-alone animals, at 12 weeks following joint
trauma [2]. However, those studies were based on higher
destructive models of OA than in our study: only a small
percentage of the horses in our study cohort sustained
an osteochondral fragmentation, all the animals of this
group were rested after the onset of lameness, and exer-
cise was suspended for a longer period of time than in
experimental studies, before to return at regular training.
Recent researches pointed out on the role of mechano-
trasduction pathway throughout the extracellular matrix,
which has a causal role in triggering OA. Biochemical
Fig. 4 Temporal course of OA biomarkers levels and corresponding clinical scores in the PTOA group. Percentual variations of OA biomarker
levels and corresponding radiographic and lameness scores, in the PTOA group of racehorses (n = 25), during 5 years of racing activity. Panel a
refers to values in the sera. Panel b refers to the synovial fluid values. Data for each time point represent the mean levels of IL-1ß, IL-6, TNF-α,
CTXII, COMP, Radiographic score and Lameness score. Standard deviation (SD) error bars are not plotted in these graphs for clarity. Reference
value at T0 is delineated (dotted line). *p < 0.05 versus level at previous time-point. **p < 0.001 versus level at previous time-point
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changes could affect the mechanical properties of HAC:
lysyl-oxidase (LOX) pathway increases cross-linking in
the collagen substrate and cartilage stiffness, LOX over-
expression affects chondrocytes activation profiles of tran-
scriptional factors, and among these the NF-kβ pathway,
which is associated to the increased expression of matrix-
degradative enzymes [42]. Modification in the pericellular
matrix in HAC has a critical role in controlling the mod-
ule of elasticity of the cartilage [43]. Chondrocytes from
OA cartilage showed an altered response to mechanical
stimulation, with an aberrant cellular signalling leading to
increased cartilage breakdown [44].
Structural biomarker levels, during progression of joint
disease, became associated with the increased level of
pro-inflammatory cytokines, when we identified more
pronounced features of inflammation. Cartilage degrad-
ation products, that are released into the SF, might induce
cytokines independent MMP-induction [45] and an in-
crease of pro-inflammatory cytokines [20]. Also COMP,
released during cartilage degradation, was able to activate
complement in the SF [46]. Furthermore, experiments
with chondrocyte cultures have clearly demonstrated that
IL-1ß and TNF-α increase cleavage of collagen type II
during OA [47].
These finding are in accordance with the observation
that targeting pro-inflammatory cytokines following joint
injury prevents PTOA in a mouse model of the disease
[32, 48, 49], like in ankylosis spondylitis [50], and
rheumatoid arthritis [51, 52] . We employed IL-1Ra, via
intra-articular pathway, to antagonize the main pro-
inflammatory cytokine, early after acute joint trauma.
Early and targeted treatment was effective to reduce
pro-inflammatory cytokines levels in the SF of affected
joints and to control cartilage degradation in the joint
tissue along an entire year. This finding raised the ques-
tion if the inflammatory status had been maintained in
the targeted joints, when pro-inflammatory cytokine
levels in the SF normalized. Inflammatory cytokines may
Table 7 Correlation between biomarkers percentual change (Δ) and percentual change of radiological score (Δ) in the subsequent
year, in PTOA affected horses only
Δ mean radiographical score of T (x+1)−T (x)
T (x) = T1 T (x) = T2 T (x) = T3
ΔIL-1b of T (x)−T (x−1) Serum – – –
Synovial Fluid – – –
ΔIL-6 of T (x)−T (x−1) Serum – – r = 0.42 (p = 0.041)
Synovial Fluid – – –
ΔTNF-a of T (x)−T (x−1) Serum – – –
Synovial Fluid – r = 0.38 (p = 0.058) r = 0.435 (p = 0.030)
ΔCOMP of T (x)−T (x−1) Serum r = 0.39 (p = 0.053) – –
Synovial Fluid – – –
ΔCTXII of T (x)−T (x−1) Serum – – –
Synovial Fluid – – –
Significant correlations are represented in bold
Table 8 Correlation between different cytokines and structural biomarkers in the PTOA affected race horses
IL-1ß IL-6 TNF-α COMP CTX-II
T0 T1 T2 T3 T4 T0 T1 T2 T3 T4 T0 T1 T2 T3 T4 T0 T1 T2 T3 T4 T0 T1 T2 T3 T4
IL-1ß S 1.0 1.0 1.0 1.0 1.0 0.40 – – – – – – – – – – – – – – – – – 0.41 –
SF 1.0 1.0 1.0 1.0 1.0 0.69 – – – – – – – 0.68 0.58 0.66 0.50 – 0.48 0.45 – – – – –
IL-6 S 1.0 1.0 1.0 1.0 1.0 – – – 0.43 – 0.53 – 0.41 – 0.52 – 0.42 – – –
SF 1.0 1.0 1.0 1.0 1.0 – – – – – 0.61 – – – – – – 0.58 – –
TNF-α S 1.0 1.0 1.0 1.0 1.0 – – – – – – – – – –
SF 1.0 1.0 1.0 1.0 1.0 – – – – – 0.51 – – 0.69 0.71
COMP S 1.0 1.0 1.0 1.0 1.0 – – – – –
SF 1.0 1.0 1.0 1.0 1.0 – – – – –
CTXII S 1.0 1.0 1.0 1.0 1.0
SF 1.0 1.0 1.0 1.0 1.0
Only the coefficients of (r) of significant groups are shown in bold, for clarity
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be expressed at higher levels in diseased cartilage [53],
and at the level of the subchondral bone [54], and syn-
ovial membrane [16] than found in evaluating the SF, as
it was detected in humane hip OA [53].
We are unable to drawn any conclusion about the
effectiveness of our therapeutic strategies during PTOA
at long-term, since the ability of such treatments to
modify disease progression is still limited.
The rapid decline of joint health, which was highlighted
in our study in the PTOA-affected racehorses, caused an
increase of joint pain and a consequent lameness. The
contribution of the pro-algesic effect of cytokines had
been recently pointed out. TNF-α and IL-1β can contrib-
ute to hyperexcitability of small-diameter unmyelinated
C-fibers, that carry pain signals from peripheral tissues to
the dorsal root ganglia [55], while IL-6 alone increases
neuronal response to substance P [55]. Contrary to what
is reported in humane knee during PTOA [56], TNF-α
level does not exhibit a clear correlation with the current
clinical scale of joint pain adopted to assess lameness in
horses. Assessment of TNF-α in the SF was able to antici-
pate radiographic deterioration in the targeted joints,
more than the percentual change of structural biomarkers.
For this reason, suppression of TNF-α could be an intri-
guing prospect in equine PTOA and requires specific
investigation.
Even if CTXII offers a useful marker reflecting on-
going cartilage damage, it was not correlated with the
radiographic score of the OA affected joints in race-
horses [27]. A weak association between the radio-
graphic parameter indicative of cartilage degradation
(JSN = joint space narrowing) and CTXII level in the SF
was detected only at T3 (p = 0.05 and r = 0.15; data not
shown). This is not surprising given that the majority of
parameters used to define the radiographic score in race-
horses’ studies are related with chronic synovitis and in-
flammation rather than to cartilage degradation. In a
terminal study in rabbits, CTXII level peaked in serum
6 weeks after experimental knee injury and subsided
during later degenerative stages, when the cartilage
destruction was complete and the joint space is reduce
[37]. Probably, this fall in the CTXII levels was not
detectable in our study, because of the less destructive
PTOA version in our animal model.
A previous study in racehorses with carpal joint injury
identified that IL-6 was increased in the joints in asso-
ciation with the presence of an osteochondral fragmen-
tation, confirming that joint fragments themselves
represent a source of inflammation [57]. Osteochondral
fragments were arthroscopically removed in our study,
and this could explain in part our results. Noteworthy,
a significant correlation between IL-6 levels in serum
and the osteophyte numbers and size, in the PTOA-
affected joints, was detectable at T3 and T4 (p < 0.05
for both; data not shown). This observation was con-
firmed in another study [58], where it was detected an
increased mRNA expression for IL-6 from osteophytes
in the OA-affected joints [58].
In contrast to CTXII, COMP in serum was able to
detect OA progression 2 years following acute joint
trauma. Moreover, COMP in the SF became significantly
different than at the previous time point concurrently
with the increasing CTXII levels in the same medium.
Clinical studies in horses obtained contrasting results re-
garding the temporal course of COMP levels in serum
and SF in early and established OA cases [28, 59–61]. It
was demonstrated a variation of COMP levels in serum
1 to 5 h after an intense exercise in healthy TBRs [28],
which returned to pre-existing values by 24 h. COMP is
preferentially expressed in the middle- and deep-layer of
the hyaline cartilage during enhanced matrix turnover
[60], but COMP fragments could not easily join the SF,
when the HAC is not structurally damaged [60]. Trend
of COMP in the serum could be related to the capacity
of osteoblasts to generate COMP [62] during subchon-
dral bone turnover. In our study, the SF level of COMP
shows a strong correlation with the lameness score at
different time-points, even if this result is difficult to
explain because it is impossible to determine the tissue
from which COMP originated.
Of note, there is a poor correlation between structural
biomarkers in the serum and SF of the PTOA-affected
joints. Only CTXII levels in the serum are correlated
with SF levels at T3 and T4. This observation is in
accordance with a mouse model of mono-iodoacetate
induced arthritis [25], where the correlation between
the biomarker values in the serum vs. SF was stronger
and it was influenced by the cytokines-mediated increased
permeability between compartments.
There are several limitations in the present study. First,
our cohort consisted of small number of subjects with
PTOA and C animals. We lacked PTOA-affected race-
horses and control healthy subjects for unrelated muscu-
loskeletal injuries, which have been retired during the
timeframe of the study. Our study design was conditioned
by the fact that female STBRs are frequently retired and
addressed to breeding at the age of 6 years old. Further
studies that include a larger cohort of animals with trau-
matic OA and a similar size group of normal animals
would be ideal for elucidating the role of many variables
during PTOA. Furthermore, more cross-sectional studies
would be necessary to clarify the role of joint treatments
and training to regulate OA progression. To clarify causal-
ity, evaluating more biomarkers during the progression of
joint disease would be required, particularly in those ani-
mals with rapid radiographic decay. A direct assessment
of HAC via whole—joint histology would provide add-
itional information but this type of approach was not
Bertuglia et al. BMC Veterinary Research  (2016) 12:246 Page 12 of 15
feasible in a clinical study. Alternatively, more direct
assessment of the articular cartilage via MRI would
have shown better correlation with the biomarker
levels, but this type of imaging was not practical for re-
peat assessments in our patients.
Conclusion
To our knowledge, this is the first study in which kinetics
of biomarkers have been evaluated at long-term during
the athletic activity of STBRs, over many years, to asses
the consequences of an acute joint injury at young age.
This study provided important information on biomarker
interplay during the clinically relevant stages of natural
joint disease in an animal model of PTOA.
The assessment of the structural and pro-inflammatory
biomarkers in the SF of the affected joints reflects the pro-
gressive evolution of PTOA towards end-stage OA and
provides the background to assess the effect of targeting
pro-inflammatory cytokines at the early stages of naturally
occurring disease. This study offers an effective prospect to
incorporate biomarker assessment in clinical trials, for the
objective monitoring of OA progression in racehorses. The
association between the initial impact-induced cartilage
damage, the treatment strategies and the progressive joint
degeneration deserves further investigation.
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